TAVR相关产品

Search documents
沛嘉医疗-B公布中期业绩 实现收入约3.53亿元 同比增长17.3%
Zhi Tong Cai Jing· 2025-08-22 14:43
Group 1 - The company reported a revenue of approximately 353 million yuan for the first half of 2025, representing a year-on-year growth of 17.3% [1] - Gross profit reached 248 million yuan, with a year-on-year increase of 13.14% [1] - Research and development expenses were about 116 million yuan, showing a year-on-year growth of 15.1% [1] Group 2 - The sustainable revenue growth is primarily attributed to strong sales growth in transcatheter valve therapy and neurointervention businesses [1] - Sales revenue from TAVR-related products increased by 24.0% to 162 million yuan, driven by market share gains in China's transcatheter aortic valve replacement market and a shift towards newly launched high-end products [1] - The total number of implants exceeded 2,050 units during the reporting period, reflecting a year-on-year growth of approximately 18.8%, surpassing market growth [1] Group 3 - Sales revenue from neurointervention products rose by 12.2% to 192 million yuan, driven by deeper market penetration of existing products and the successful launch of the newly approved YonFlow blood flow-directed mesh stent [1] - The DCwire microcatheter, launched commercially in 2024, significantly expanded market share with a revenue growth of nearly 140% [2] - The YonFlow blood flow-directed mesh stent received regulatory approval in April 2025 and achieved its first commercial implant by June 2025, with procurement completed in over 20 provinces [2]
沛嘉医疗-B(09996)公布中期业绩 实现收入约3.53亿元 同比增长17.3%
智通财经网· 2025-08-22 14:40
Core Insights - The company reported a revenue of approximately 353 million yuan for the first half of 2025, representing a year-on-year growth of 17.3% [1] - Gross profit reached 248 million yuan, with a year-on-year increase of 13.14% [1] - Research and development expenses amounted to about 116 million yuan, reflecting a year-on-year growth of 15.1% [1] Revenue Growth Drivers - The sustainable revenue growth is primarily attributed to strong sales growth in the transcatheter valve therapy and neurointervention businesses [1] - Sales revenue from TAVR-related products increased by 24.0% to 162 million yuan, driven by market share gains in the Chinese TAVR market and a shift towards newly launched high-end products [1] - Total terminal implants exceeded 2,050 units, marking a year-on-year growth of approximately 18.8%, surpassing market growth [1] Neurointervention Product Performance - Sales revenue from neurointervention products rose by 12.2% to 192 million yuan, with key drivers including deeper market penetration of existing products and the successful launch of the newly approved YonFlow® blood flow-directed stent [1] - The DCwire® microcatheter significantly expanded market share with a revenue growth of nearly 140% during the reporting period [2] - The YonFlow® blood flow-directed stent received regulatory approval in April 2025 and has been actively marketed, achieving its first commercial implant by June 2025 [2]
沛嘉医疗-B(09996.HK)中期业绩:收入同比增17.3% 核心业务板块销售强劲
Ge Long Hui· 2025-08-22 14:35
Core Viewpoint - Peijia Medical-B (09996.HK) reported a revenue of RMB 353.4 million for the six months ending June 30, 2025, representing a 17.3% increase compared to the same period in 2024, driven by strong sales growth in both transcatheter aortic valve replacement (TAVR) and neurointerventional products [1] Revenue Composition - Revenue composition remained stable, with 45.7% from TAVR-related product sales and 54.3% from neurointerventional product sales, compared to 43.3% and 56.7% respectively in the first half of 2024 [1] TAVR Product Sales - TAVR-related product sales increased by 24.0% year-on-year to RMB 161.6 million, driven by market share gains in China's transcatheter aortic valve market and a shift towards newly launched high-end products [1] - Total implantations exceeded 2,050 units during the reporting period, reflecting an approximate 18.8% year-on-year growth, surpassing market growth [1] Neurointerventional Product Sales - Neurointerventional product sales rose by 12.2% year-on-year to RMB 191.8 million, with key drivers including deeper market penetration of existing products (such as DCwire® microcatheter, Tethys AS® aspiration catheter, and Fastunnel® balloon delivery catheter) and the successful launch of the newly approved YonFlow® flow-directed stent [1]
6.15亿!增长39.5%!沛嘉医疗最新年报
思宇MedTech· 2025-03-27 09:24
报名:首届全球眼科大会 | 议程更新 报名:首届全球心血管大会 | 奖项申报 报名:首届全球骨科大会 | 奖项评选 合作伙伴征集:2025全球手术机器人大会 心未来 2025年3月26日, 沛 嘉医疗-B (09996.HK)发布截至2024年12月31日止年度业绩公告。 # 财报数据 报告期内,公司 收入达到6.15亿元人民币,同比增长39.53% 。其中,TAVR相关产品销售收入同比增长 40.1%至2.60亿元,占总收入的 42.2% ;神经介入产品销售收入同比增长39.1%至3.56亿元,占总收入的 57.8% 。 股东应占亏损 :2024年股东应占亏损2.27亿元,同比收窄42.28%。 每股基本亏损 :0.34元。 | 財務摘要 | | | | | --- | --- | --- | --- | | | 截至12月31日止年度 | | | | | 2024年 | 2023年 | 同比參動 | | | 人民幣千元 人民幣千元 | | | | 收入 | 615,483 | 441.126 | 39.5% | | 毛利 | 433.621 | 325.370 | 33.3% | | 銷售及分銷開支 | ...
沛嘉医疗2024年经营亏损同比收窄44.4% 神经介入业务成为首个盈利板块
Mei Ri Jing Ji Xin Wen· 2025-03-26 04:44
Core Insights - The company reported a revenue of 616 million yuan for 2024, representing a year-on-year growth of 39.5%, while operating losses narrowed by 44.4% to 239 million yuan [1][2] - The neurointervention segment became the first profitable business unit, contributing a profit of 52.1 million yuan [1] Revenue Composition - Revenue composition remained stable, with 42.2% from TAVR-related product sales and 57.8% from neurointervention product sales [1] - TAVR-related product sales increased by 40.1% year-on-year to 260 million yuan, while neurointervention product sales rose by 39.1% to 356 million yuan [1] Growth Drivers - Revenue growth was primarily driven by high sales growth in the transcatheter valve therapy and neurointervention businesses [2] - TAVR-related product revenue growth was attributed to an increase in market share in China's transcatheter aortic valve replacement market, with total implantations exceeding 3,400 units, a year-on-year increase of approximately 37% [2] - The neurointervention product revenue growth was supported by improved surgical penetration rates, successful bids in volume-based procurement, and a comprehensive product pipeline with effective marketing strategies [2] Cost Management - Research and development expenditure ratio decreased from 66.5% to 33.1%, a decline of 33.4 percentage points, due to revenue growth and products entering a lower expenditure phase [2] - The sales and distribution expense ratio fell by 20.3 percentage points to 53.5%, resulting in a commercial profit of 105 million yuan [2] - Administrative expenses remained stable over the past few years, with the administrative expense ratio decreasing from 32.1% to 24.5%, a year-on-year decline of 7.6 percentage points [2]